公开(公告)号：US20230137672A1

公开(公告)日：2023-05-04

申请号：US17913189

申请日：2021-03-26

申请人： THE TRUSTEES OF INDIANA UNIVERSITY

发明人： Fabiana PERNA

IPC分类号： C07K14/725 ,  C12Q1/6886 ,  G01N33/574

摘要： Surface proteins predominantly associated with multiple myeloma are identified as potential targets for developing anti-multiple myeloma therapeutics. In accordance with one embodiment antibodies are generated that specifically bind to epitopes of the identified protein that are associated with multiple myeloma cells. These antibodies can then be used to target the delivery of cytotoxic agents to multiple myeloma cells in a patient or used to prepare CAR T-cells for the treatment of multiple myeloma patients.

公开(公告)号：US20230133761A1

公开(公告)日：2023-05-04

申请号：US17801547

申请日：2021-03-11

申请人： Heinrich-Heine-Universität Düsseldorf

发明人： Knud Esser ,  Andrea Kulik ,  Tanja Fehm ,  Judith Steimel

IPC分类号： G01N33/50 ,  G01N33/574

摘要： The invention relates to a method for finding inhibitors of the peptidyl-prolyl cis-trans isomerase FKBP1A or antibodies, proteins or molecules having a specific affinity to FKBP1A. The invention also relates to FKBP1A-specific siRNA, inhibitors of the expression of FKBP1A, inhibitors of the enzymatic activity of FKBP1A, and inhibitors of the interaction(s) of FKBP1A with interaction partner(s), in each case for the treatment of diseases, in particular cancers or neurodegenerative diseases. The invention further relates to the use of FKBP1A as a prognostic or diagnostic marker for cancers. The cancers are preferably mammary carcinoma, in particular triple-negative mammary carcinoma, in this case very particularly the mesenchymal stem-like sub-type.

公开(公告)号：US11639940B2

公开(公告)日：2023-05-02

申请号：US16832569

申请日：2020-03-27

申请人： SYSMEX CORPORATION

发明人： Noriko Yokose ,  Kenta Noda

IPC分类号： G01N1/00 ,  G01N33/68 ,  G01N33/574 ,  G01N33/573 ,  C12Q1/48 ,  G01N33/15 ,  C07K16/30 ,  G01N33/487

摘要： Disclosed is a method for determining sensitivity to a CDK4/6 inhibitor, comprising the steps of: comparing a value based on activity of at least one CDK selected from CDK4 and CDK6 in a sample collected from a subject, with a threshold level corresponding to the CDK, and determining that the subject is insensitive to the CDK4/6 inhibitor when the value based on the CDK activity is less than the threshold level.

公开(公告)号：US20230129844A1

公开(公告)日：2023-04-27

申请号：US17912171

申请日：2021-03-19

申请人： AMGEN INC.

发明人： Kurt Edelmann ,  Julie Bailis

IPC分类号： G01N33/574 ,  G01N33/531

摘要： The present invention relates to antibodies that bind to human and monkey mucin 17 (MUC17). Moreover, the invention relates to a detection system comprising such antibodies. The antibodies or the detection system may be used for detecting or quantifying MUC17, for diagnosing a disease associated with MUC17, for patient stratification, monitoring disease progression, and evaluating the therapeutic response.

公开(公告)号：US20230127069A1

公开(公告)日：2023-04-27

申请号：US17933446

申请日：2022-09-19

申请人： Aspira Women's Health Inc.

发明人： Herbert FRITSCHE ,  Lesley NORTHROP

IPC分类号： G01N33/574

摘要： The present invention provides compositions and methods having improved specificity and sensitivity for the pre-operative assessment of ovarian tumors (e.g., symptomatic and asymptomatic adnexal mass) in a variety of subjects (e.g., pre- and post-menopausal women) having a variety of ovarian cancer types (e.g., low malignant potential, intermediate malignant potential, high malignant potential).

公开(公告)号：US11635434B2

公开(公告)日：2023-04-25

申请号：US16681494

申请日：2019-11-12

申请人： Andrew L. Mason ,  Mandana Rahbari ,  Guangzhi Zhang

发明人： Andrew L. Mason ,  Mandana Rahbari ,  Guangzhi Zhang

IPC分类号： G01N33/574 ,  A61K35/17 ,  G01N33/68 ,  A61K45/06 ,  C07K14/195 ,  A61K38/00

摘要： Methods for determination of risk, previous history and/or presence of a betaretrovirus infection in a subject are described herein. Said methods may comprise incubating a biological sample from the subject, the biological sample comprising immune effector-producing cells, with one or more betaretrovirus-specific epitopes, the betaretrovirus-specific epitopes comprising at least 7 contiguous amino acids according to any one of SEQ ID Nos. 1-36, and measuring the production of immune effectors by the immune effector-producing cells, wherein production of the immune effectors by the immune effector-producing cells determines risk and/or presence of betaretrovirus infection in the subject. Isolated peptides and kits for carrying out the methods are also described.

公开(公告)号：US11634487B2

公开(公告)日：2023-04-25

申请号：US16625754

申请日：2018-07-05

申请人： AVA Lifescience GmbH

发明人： Ulrich Birsner ,  Hassan Jumaa ,  Holger Klapproth ,  Marc A. Kessemeier

IPC分类号： C07K16/28 ,  A61P35/02 ,  C07K16/30 ,  G01N33/574

摘要： The present invention relates to the field of production, identification and selection of biological binding molecules such as antibodies or fragments thereof, as well as to diagnostic procedures using them in the diagnosis of cancers, in particular malignant B-cell neoplasia. The binding molecules are able to selectively bind to autonomously active or autonomously activated B-cell receptors, the autonomously active or autonomously activated B-cell receptors being characterized by the presence of structural domains to which the binding molecule selectively binds and which are responsible for the autonomously active or autonomously activated state of the B-cell receptors.

公开(公告)号：US20230123148A1

公开(公告)日：2023-04-20

申请号：US17907348

申请日：2021-03-26

申请人： UNIVERSITEIT GENT

发明人： Bart DE SPIEGELEER ,  Evelien WYNENDAELE ,  Christophe VAN DE WIELE ,  Olivier DE WEVER ,  Nathan DEBUNNE

IPC分类号： A61K35/747 ,  G01N33/574 ,  A61P35/04 ,  G01N33/68

摘要： Quorum-sensing peptides are provided as diagnostic biomarkers, and quorum-sensing peptide inhibiting substances are provided for use in the treatment of metastasis of colorectal cancer in a subject, in particular a human subject. Methods for reducing metastasis of colorectal cancer in a subject include administering to the subject a microorganism that reduces or blocks activity of a pro-metastatic quorum-sensing peptide or a metabolite thereof present in a gastrointestinal tract or blood of the subject; and/or that reduces or blocks production of the pro-metastatic quorum-sensing peptide or the metabolite thereof in the gastrointestinal tract or blood of the subject. The pro-metastatic quorum-sensing peptide may include EntF or the metabolite EntF* of EntF.

公开(公告)号：US20230118302A1

公开(公告)日：2023-04-20

申请号：US17728491

申请日：2022-04-25

申请人： Zymeworks Inc.

发明人： Nina E. Weisser ,  Gordon Yiu Kon Ng ,  Grant Raymond Wickman ,  Surjit Bhimarao Dixit ,  Eric Escobar-Cabrera ,  Mario Sanches

IPC分类号： C07K16/32 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30 ,  G01N33/574

摘要： Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

公开(公告)号：US20230116279A1

公开(公告)日：2023-04-13

申请号：US17929347

申请日：2022-09-02

申请人： Immatics Biotechnologies GmbH

发明人： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC分类号： C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.